Over the past 10 years, nearly 60 years with the launch of the largest drug companies，"Forbes' senior editor Matthew Herper recently quoted Bernard Munos for nearly 10 years with the introduction of new drugs for nearly 60 years, most enterprise data .

Novartis (established in 1996) higher than the GlaxoSmithKline (established 2000) 7 the number of new drugs ahead, came in nearly 10 years to launch the top drug companies.

Munos that Novartis benefited from the success of groundbreaking innovation bet. In response, Novartis executives also agreed. Merck, Eli Lilly, Pfizer, Johnson & Johnson and other pharmaceutical giants launch new drugs in the annual rate of about 0.8 to 1.

Although the pharmaceutical industry, the amount of drug released remained relatively stable, linear growth, but investment in new drug research and development has increased exponentially. Huge increase in R & D investment and innovation or does not improve the productivity of drug development. Most people believe that pharmaceutical companies to invent a new drug takes 10 billion, but Munos that this figure is 40 billion dollars, no doubt to the pharmaceutical industry, investors tells an amazing fact.

61-year-old Munos is at Lilly for 30 years. Over the past 10 years, he has been trying to answer questions about drug development is an important issue: the pharmaceutical company has successfully developed new drugs what is the secret in the end - why so many companies fail? Why do pharmaceutical companies spend billions each year in R & D funding, innovation, efficiency is so low? This measure also find efficient and effective research tool for model outputs.
Munos in recent years in "Nature" magazine published two papers to illustrate their point of view. Among them, the articles published in 2006 highlighted the new computer software technology platform in the open mode is used.

Munos said the increase in R & D investment and the rate of drug release is not relevant, therefore, he strongly recommended the company should cut R & D R & D costs. Throughout Munos R & D of new drugs for the pharmaceutical industry recommendations about the following four points: First, reduce R & D investment. Two: change the traditional closed model for open R & D R & D model, the three: a breakthrough innovation. Four: R & D outsourcing. (From Medicine Economic News)